INDP earnings date and last-quarter result: next report 2026-08-17, last quarter beat, P/E -0.42. Updated 2026-07-23.
Indaptus Therapeutics (INDP) Research Hub
Indaptus Therapeutics (INDP) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 3.34 USD (+5.70%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.42, market cap 0.00B. This hub links to the full technical, earnings and options research available for INDP.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.34 USD (+5.70%) |
| 52-week range | 0.925 USD – 4.94 USD |
| Trend regime | Range |
| 14-day RSI | 63.4 (Bullish) |
| Trailing P/E | -0.42 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-17 |
Available research for INDP
Covered Call on INDP: how it works, illustrative setup around the real 3.34 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on INDP: how it works, illustrative setup around the real 3.34 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on INDP: how it works, illustrative setup around the real 3.34 USD price, max profit/loss, breakeven and when to use it. Educational.
INDP technical analysis: range, last 3.34 USD, RSI 63.4, 52w range 0.925 USD–4.94 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is INDP in?
Indaptus Therapeutics (INDP) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is INDP in an uptrend or downtrend?
As of 2026-10-26, INDP is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is INDP's trailing P/E ratio?
INDP's trailing P/E is -0.42, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does INDP next report earnings?
INDP is next scheduled to report earnings on 2026-08-17.